Results 241 to 250 of about 4,586,589 (282)

Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis

International Journal of Molecular Sciences, 2023
Over the past 30 years, the majority of (pre)clinical efforts to find an effective therapy for Alzheimer’s disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain since, according to the amyloid cascade hypothesis, the peptide was (and it is still considered by many) the pathogenic determinant of this neurodegenerative disorder ...
Ernesto Fedele
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Will Anti-Amyloid Therapies Work for Alzheimer's Disease?

Lancet, The, 2008
Peter Henry St George-Hyslop
exaly   +3 more sources

Anti-Amyloid Antibody Therapies for Alzheimer’s Disease

Nuclear Medicine and Molecular Imaging
Alzheimer's disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely difficult to treat and severely reduces quality of life. Amyloid beta (Aβ) has been the primary target of experimental therapies owing to the neurotoxicity of Aβ and the brain Aβ load detected in humans by ...

exaly   +3 more sources

Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects

Biochemistry (Moscow), 2018
Drug development for the treatment of Alzheimer's disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned.
S A, Kozin, E P, Barykin, V A, Mitkevich, A A, Makarov   +3 more
openaire   +2 more sources

Treatment-Related Amyloid Clearance (TRAC): A Framework to Characterize Patients in the Era of Anti-Amyloid Therapies [PDF]

Alzheimer's and Dementia
Following regulatory approval of anti-amyloid beta (Aβ) therapies, a better characterization of patients receiving these treatments is needed to guide clinical management and inclusion in future trials.
Christopher H. van Dyck, Renaud La Joie, Susan M Landau   +2 more
exaly   +2 more sources

Current Status and Prospect of Anti-Amyloid Fibril Therapy in AL Amyloidosis

Blood Reviews
Amyloid light-chain (AL) amyloidosis is a rare hematological disease that produces abnormal monoclonal immunoglobulin light chains to form amyloid fibrils that are deposited in tissues, resulting in organ damage and dysfunction. Advanced AL amyloidosis has a very poor prognosis with a high risk of early mortality.
Liye Zhong
exaly   +3 more sources

They Are Here: Anti-Amyloid Therapies to Treat Dementia

The Senior Care Pharmacist
The US Food and Drug Administration’s approval of anti-amyloid therapies for the treatment of Alzheimer’s dementia has resulted in a proliferation of publications reporting and conveying rapidly changing information. Unfortunately for the clinician, this information is surfacing in a variety of places and formats without a unifying consensus or clear ...
exaly   +3 more sources

Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer’s disease

Neurobiology of Aging, 2002
Amyloid is a generic description applied to a heterogeneous class of tissue protein precipitates that have the common feature of beta-pleated sheet secondary structure, a characteristic that confers affinity of the protein deposit for the histochemical dye Congo red.
openaire   +2 more sources

The Development of Anti-Amyloid Therapy for Alzheimer???s Disease

CNS Drugs, 2005
The leading hypothesis of the pathophysiology of Alzheimer's disease holds that the pivotal event is cleavage of the amyloid precursor protein to release intact the 42-amino-acid amyloid-beta peptide (Abeta); this hypothesis best explains the known genetic causes of Alzheimer's disease.
openaire   +2 more sources